Stockscreener 앱 받기
1.53
0.00%
0.00
시간 외 거래:
1.56
0.03
+1.96%
전일 마감가:
$1.53
열려 있는:
$1.52
하루 거래량:
221.14K
Relative Volume:
3.27
시가총액:
$40.25M
수익:
$9.06M
순이익/손실:
$-50.39M
주가수익비율:
-0.7969
EPS:
-1.92
순현금흐름:
$5.89M
1주 성능:
+7.75%
1개월 성능:
+12.76%
6개월 성능:
+60.13%
1년 성능:
-13.07%
1일 변동 폭
$1.52
$1.56
1주일 범위
$1.3733
$1.56
52주 변동 폭
$0.8502
$2.093
Lava Therapeutics Nv Stock (LVTX) Company Profile
명칭
Lava Therapeutics Nv
전화
31 6 3000 3035
주소
YALELAAN 62, UTRECHT
LVTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
1.53 | 40.25M | 9.06M | -50.39M | 5.89M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-12 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-25 | 개시 | H.C. Wainwright | Buy |
| 2021-04-19 | 개시 | JP Morgan | Overweight |
| 2021-04-19 | 개시 | Jefferies | Buy |
| 2021-04-19 | 개시 | SVB Leerink | Outperform |
모두보기
Lava Therapeutics Nv 주식(LVTX)의 최신 뉴스
Signal strength of LAVA Therapeutics N.V. stock in tech scannersAI Pattern Recognition and Trade Prediction - Newser
Is LAVA Therapeutics N.V. stock poised for growthFree Multi-Bagger Potential Stock Forecast Tools - Newser
Automated trading signals detected on LAVA Therapeutics N.V.Free Swing Trading Entry Point Signals - Newser
What earnings revisions data tells us about LAVA Therapeutics N.V.Trading Opportunities Forecast by AI Insight - Newser
Is it too late to sell LAVA Therapeutics N.V.Intraday Strategy with Real Time Monitoring - Newser
How LAVA Therapeutics N.V. stock performs during market volatilityPattern Breakout Tracker with Screener Tools - Newser
Published on: 2025-08-09 21:31:18 - Newser
Can a trend reversal in LAVA Therapeutics N.V. lead to recoveryFree Risk-Adjusted Picks With Exit Strategy - Newser
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LAVA Therapeutics N.V. (NASDAQ: LVTX) - Eastern Progress
XOMA Royalty Announces Dual Acquisitions of HilleVax and LAVA Therapeutics - MSN
Will breakout in LAVA Therapeutics N.V. lead to full recoveryRisk Managed Watchlist with Breakout Picks - Newser
Is a relief rally coming for LAVA Therapeutics N.V. holdersHistorical Stock Summary and ROI Review - Newser
Real time scanner hits for LAVA Therapeutics N.V. explained3-Day Market Movement Forecast Analysis - Newser
Has LAVA Therapeutics N.V. formed a bullish divergenceFree Entry Plan for Oversold Reversal Stocks - Newser
Tools to assess LAVA Therapeutics N.V.’s risk profileCapital Growth Plan for New Investors - Newser
LAVA Therapeutics (NASDAQ:LVTX) Cut to “Hold” at Jefferies Financial Group - Defense World
Investigation into Steelcase, LAVA Therapeutics, and Enzo Biochem on Behalf of Shareholders - AInvest
Live market analysis of LAVA Therapeutics N.V.Stock Forecast Tools for Retail Traders - Newser
East Bay’s Xoma adds two more biotechs to its portfolio - The Business Journals
Real time breakdown of LAVA Therapeutics N.V. stock performanceFree Access to Smart Investment Tips - Newser
Jefferies downgrades Lava Therapeutics stock to Hold on XOMA acquisition By Investing.com - Investing.com Australia
Jefferies downgrades Lava Therapeutics stock to Hold on XOMA acquisition - Investing.com
Xoma Royalty Enters Into Agreement To Acquire Lava Therapeutics For Between $1.16 and $1.24 per Share in Cash, Plus a Contingent Value Right - citybiz
Xoma strikes deals to buy struggling biotechs HilleVax, Lava - BioPharma Dive
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
LAVA Therapeutics stock rises on acquisition deal with XOMA Royalty - Investing.com
LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders - Business Wire
LAVA Therapeutics stock rises on acquisition deal with XOMA Royalty By Investing.com - Investing.com South Africa
XOMA signals full tender offer for LVTX; deal terms pending | LVTX SEC FilingForm SC TO-C - Stock Titan
LAVA Therapeutics Agrees to Acquisition by XOMA - TipRanks
XOMA Royalty to acquire HilleVax and LAVA Therapeutics in separate deals - Investing.com Canada
XOMA Royalty to Acquire LAVA Therapeutics for $1.16-$1.24 per Share - AInvest
LVTX to be Acquired by XOMA for $1.16-$1.24 Cash Plus CVR | LVTX SEC FilingForm 8-K - Stock Titan
XOMA Royalty to acquire LAVA Therapeutics for $1.16-$1.24 per share. - AInvest
XOMA Royalty Enters into Agreement to Acquire LAVA - GlobeNewswire
Press Release: XOMA Royalty Enters Into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right - 富途牛牛
What are LAVA Therapeutics N.V. company’s key revenue driversRecord-breaking capital gains - Jammu Links News
How Resilient Is LAVA Therapeutics N.V. Stock During Economic DownturnsAI Powered Stock Market Trend Forecast - Newser
When is LAVA Therapeutics N.V. stock expected to show significant growthAccess high-yield investment alerts now - Jammu Links News
What drives LAVA Therapeutics N.V. stock priceFree Stock Movement Tracking - Jammu Links News
Is LAVA Therapeutics N.V. stock overvalued or undervaluedMaximize returns with disciplined investment techniques - Jammu Links News
How strong is LAVA Therapeutics N.V. company’s balance sheetCapitalize on high-yield stock opportunities - Jammu Links News
What institutional investors are buying LAVA Therapeutics N.V. stockHigh-yield market plays - Jammu Links News
What makes LAVA Therapeutics N.V. stock price move sharplyOverwhelming financial success - Jammu Links News
Published on: 2025-08-03 16:45:37 - Jammu Links News
What are the technical indicators suggesting about LAVA Therapeutics N.V.Free Market Dynamics Reports - Jammu Links News
Lava Therapeutics Nv (LVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):